Next stop: clinical testing
Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its JEREMIE fund – basically European money, as the acronym stands for “Joint European Resources for Micro to Medium Enterprises”. JEREMIE is a joint initiative of Andalusia’s Regional Government, the European Commission and the European Investment Fund. The new funding will allow nLife Therapeutics to bring its compounds to the clinical trial stage and efficacy testing in humans. Launched in 2009 after successfully showing that siRNA therapeutics can be targeted to monoaminergic neurons in mice, nLife is pursuing treatments for Parkinson’s Disease, Major Depression Disorder (MDD) and Morbid Obesity with its siRNAs.